 |
| 13-May-13 | Reiterated |
MKM Partners |
Neutral |
$57 → $54 |
|
| 25-Apr-13 | Reiterated |
MKM Partners |
Neutral |
$53 → $57 |
|
| 15-Apr-13 | Reiterated |
Barclays |
Equal Weight |
$52 → $55 |
|
| 30-Jan-13 | Reiterated |
UBS |
Neutral |
$51 → $54 |
|
| 14-Jan-13 | Reiterated |
Argus |
Buy |
$55 → $60 |
|
| 07-Jan-13 | Reiterated |
UBS |
Neutral |
$49 → $51 |
|
| 07-Jan-13 | Reiterated |
Barclays |
Equal Weight |
$46 → $49 |
|
| 20-Dec-11 | Initiated |
MKM Partners |
Sell |
$33 |
|
| 14-Sep-11 | Reiterated |
Barclays Capital |
Equal Weight |
$42 → $39 |
|
| 22-Jul-11 | Reiterated |
UBS |
Neutral |
$36 → $38 |
|
| 13-Aug-10 | Reiterated |
MP Advisors |
Outperform |
$43 → $41 |
|
| 12-Mar-10 | Initiated |
Jefferies & Co |
Buy |
$41 |
|
| 29-Jan-10 | Reiterated |
Credit Suisse |
Neutral |
$37 → $36 |
|
| 16-Dec-09 | Initiated |
UBS |
Neutral |
|
|
| 11-Dec-09 | Downgrade |
Caris & Company |
Above Average → Average |
$40 → $34 |
|
| 09-Oct-09 | Initiated |
Wells Fargo |
Market Perform |
|
|
| 19-Aug-09 | Reiterated |
Caris & Company |
Above Average |
$43 → $40 |
|
| 21-Apr-09 | Upgrade |
Caris & Company |
Average → Above Average |
|
|
| 07-Apr-09 | Downgrade |
Leerink Swann |
Mkt Perform → Underperform |
|
|
| 18-Mar-09 | Upgrade |
Citigroup |
Hold → Buy |
$36 → $41 |
|
|
|
| 17-May-13 06:34PM | Abbott Laboratories Stock Checkup for May at Motley Fool |
| 10:43AM | Stanley Druckenmiller's top stock picks at MarketWatch |
| 10:40AM | Diagnosing Alzheimer's First at Motley Fool |
| 12:01AM | Lilly, ThyssenKrupp, Adidas, AMD: Intellectual Property at Bloomberg |
| 16-May-13 06:32PM | Any Light at the End of the Tunnel for Alzheimer's Disease? at Motley Fool |
| 05:05PM | Cheerleaders: Look Beyond Pharma For Jobs YCharts |
| 02:12PM | Canada Supreme Court Wont Hear Eli Lilly Zyprexa Appeal at Bloomberg |
| 01:40PM | What Will $2 Million Get You In Retirement? at Seeking Alpha |
| 01:17PM | This Sector Is No Bargain at Motley Fool |
| 01:04PM | AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward at TheStreet |
| 11:06AM | 2 Scariest Dividend Stocks in Health Care at Motley Fool |
| 15-May-13 01:42PM | These Stocks Are Still Solid Long-Term Picks at Motley Fool |
| 01:28PM | Is Vivus a Buy at These Prices? at Wall St. Cheat Sheet |
| 14-May-13 06:30PM | What Does This Failure Mean for Eli Lilly Investors? at Motley Fool |
| 06:21PM | Jolie Mastectomy Fuels Debate on Breast Cancer Treatment at Bloomberg |
| 04:30PM | Lilly Oncology to Release New Pipeline Data at ASCO 2013 PR Newswire |
| 04:20PM | Amgen to Set Up JV in China Zacks |
| 03:28PM | Don't Get Too Excited About This Cancer Drug Yet at Motley Fool |
| 11:08AM | Lilly CEO recovering after repair to aorta at Reuters |
| 10:33AM | Jolie Has Double Mastectomy to Thwart Cancer Gene Risk at Bloomberg |
| 09:53AM | Lilly CEO Lechleiter Has Surgery to Repair Heart at Bloomberg |
| 09:00AM | Lilly Provides Update on CEO Dr. John Lechleiter PR Newswire |
| 01:58AM | Big Pharma's Biggest Losers at Motley Fool |
| 13-May-13 12:45PM | [video] Are Women Still Buying Coach? at CNBC |
| 11:00AM | Lilly Scraps Oncology Candidate Zacks |
| 09:53AM | Eli Lilly And Stock To Go Ex-dividend Tomorrow (LLY) at TheStreet |
| 12-May-13 06:00PM | Curing Back Pain and Preventing Diabetes at Motley Fool |
| 04:31PM | Merck Stock: Not a Safe Pick for Dividend Investors at Motley Fool |
| 11-May-13 02:36PM | London-Based Hedgie Focusing On Big Pharma at Motley Fool |
| 11:30AM | This Week in Biotech at Motley Fool |
| 10-May-13 04:17PM | Lilly Stops Trial of Lymphoma Drug Due to Ineffectiveness at Bloomberg |
| 03:41PM | 6 Big Pharma Stocks With Lower Credit Risk Than U.S. Treasuries: Part I at Motley Fool |
| 01:06PM | Eli Lilly ends development of lymphoma drug AP |
| 11:42AM | Marketing Without Innovation: a Merck Story YCharts |
| 10:50AM | MannKind's Countdown to Liftoff? at Motley Fool |
| 10:24AM | Eli Lilly & Co. About To Put More Money In Your Pocket at Forbes |
| 10:14AM | Eli Lilly lymphoma drug fails in late-stage trial at Reuters |
| 08:24AM | Eli Lilly's lymphoma drug fails in late-stage trial at Reuters |
| 08:15AM | Lilly Stops Trial of Lymphoma Drug Due to Ineffectiveness at Bloomberg |
| 08:05AM | InPlay: Eli Lilly announces Enzastaurin Phase III study did not meet primary endpoint in Diffuse Large B-Cell Lymphoma; reaffirms guidance Briefing.com |
| 08:00AM | Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma PR Newswire |
| 09-May-13 10:02PM | Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived at Seeking Alpha |
| 08:45PM | Lilly To Take $30M Charge After Relapse Cancer Drug Disappoints in Trial at Fox Business |
| 06:07PM | Pharmas Failure: Drug Spending Finally Declines YCharts |
| 04:45PM | Adasuve Deal Is Very Good For Alexza, But What About Teva? at Investopedia |
| 02:48PM | State pharmacy boards back more FDA oversight AP |
| 07:30AM | Why Drug Giants Are Selling Fewer Pills Than They Used To at Forbes |
| 07:30AM | Big Drug Companies Are Selling Fewer Pills, But Charging More at Forbes |
| 07:00AM | Bristol-Myers, Disney, Google: Intellectual Property at Bloomberg |
| 08-May-13 11:59PM | U.S. spending on medicines fell for first time in 2012 at Reuters |
| 02:55PM | For Farmers, Rise in Suicide Rate Is Old News at Minyanville |
| 02:49PM | REUTERS SUMMIT-Faster drug approvals a tonic for pharma industry at Reuters |
| 02:25PM | The Next Billionaire: A Statistician Who Changed Medicine at Forbes |
| 02:03PM | Congress Members Sprint for Money to Lobby After Election at Bloomberg |
| 09:43AM | Why Psychiatry's Seismic Shift Will Happen Slowly at Forbes |
| 07-May-13 08:00PM | Congress Members Sprint for Money to Lobby After Election at Bloomberg |
| 07:18PM | Bristol-Myers Sues Genentech Over Cabilly Patents at Bloomberg |
| 06:18PM | Picking Up the Pieces of Another Alzheimer's Failure at Motley Fool |
| 04:42PM | 3 Bio Companies Facing The Patent Cliff at Seeking Alpha |
| 04:06PM | Baxter Immunoglobulin Fails to Aid Alzheimers Patients at Bloomberg |
| 02:20PM | [$$] Baxter Can Bounce Back at Barrons.com |
| 02:14PM | Baxter's Alzheimer's disease drug fails in late-stage trial at Reuters |
| 02:02PM | Pfizer Online Viagra Sales: Big Shift Or No Big Deal? at Investor's Business Daily |
| 01:56PM | Daily Dividend Report: MSI, LLY, EMR, ALV, TSN at Forbes |
| 01:03PM | 4 Stocks Pushing The Drugs Industry Downward at TheStreet |
| 11:41AM | Promising Alzheimers Treatment Fails, Drug Maker Says at New York Times |
| 11:41AM | Alzheimers Treatment Failed Trial, Maker Says at New York Times |
| 11:41AM | Promising Alzheimers Treatment Fails, Drug Maker Says at New York Times |
| 09:15AM | This Contradiction In Baxter's Data Will Make Alzheimer's Researchers Nervous at Forbes |
| 08:29AM | Failure Of Baxter's Trial Another Blow To Alzheimer's Treatment at Forbes |
| 08:14AM | Looking For Real Viagra? Head to the Internet. at Motley Fool |
| 07:59AM | Early Movers: DIS, EA, OMX & More at CNBC |
| 12:08AM | Eli Lilly CEO Taking Leave of Absence at Motley Fool |
| 06-May-13 08:58PM | Eli Lilly Declares Q2 Dividend at Motley Fool |
| 06:44PM | InPlay: Eli Lilly and Boehringer Ingelheim Pharmaceuticals announce results from two new pooled analyses of phase 3 data with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin Briefing.com |
| 06:38PM | Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress PR Newswire |
| 05:54PM | [$$] Lilly CEO to Have Artery Surgery at The Wall Street Journal |
| 05:44PM | Lilly CEO to undergo surgery, CFO Rice to become interim CEO Reuters |
| 05:42PM | Lilly CEO to undergo surgery, CFO Rice to become interim CEO at Reuters |
| 05:37PM | Lillys CEO Lechleiter Plans Surgery for Dilated Artery at Bloomberg |
| 05:27PM | Lilly CEO Lechleiter to undergo surgery for dilated aorta Reuters |
| 05:09PM | Bashful men can buy the little blue pill online AP |
| 05:08PM | Bashful men can buy the little blue pill online AP |
| 05:02PM | Lilly CEO Lechleiter to undergo surgery for dilated aorta at Reuters |
| 05:00PM | Eli Lilly: CEO Lechleiter will have aorta surgery AP |
| 04:58PM | Bashful men can buy the little blue pill online AP |
| 04:45PM | After AbbVie's Humira: What Next? at Seeking Alpha |
| 04:32PM | InPlay: Eli Lilly Announces CEO Dr. John Lechleiter to undergo scheduled surgery; expected to make a full recovery and return to his duties later this summer Briefing.com |
| 04:30PM | Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery PR Newswire |
| 02:48PM | Bashful? Buy the little blue pill online AP |
| 02:30PM | Lilly Declares Second-Quarter 2013 Dividend PR Newswire |
| 01:03PM | Bashful? Buy the little blue pill online AP |
| 11:30AM | Mondays movers: Apple gains on price-target hike at MarketWatch |
| 10:21AM | Mondays movers: Berkshire rises on robust results at MarketWatch |
| 09:41AM | LILLY ELI & CO Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online |
| 08:36AM | Monday movers: Cliffs Natural, Tyson Foods at MarketWatch |
| 08:14AM | Monday movers: Cliffs Natural, Tyson Foods at MarketWatch |
| 08:13AM | Bashful? Buy the little blue pill online AP |
| 07:27AM | Bashful? Buy the little blue pill online AP |
| 06:17AM | Bashful? Buy the little blue pill online AP |
|
|
| Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's neuroscience products treat major depressive disorders; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; bipolar depression and treatment-resistant depression; and brain imaging of beta-amyloid plaques. Its endocrinology products treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. The company's oncology products treat malignant pleural mesothelioma; pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as cardiovascular products, which are used treat erectile dysfunction, benign prostatic hyperplasia, high cholesterol, pulmonary arterial hypertension; reduce thrombotic cardiovascular events; and used as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to improve milk productivity in dairy cows; anticoccidial agents; antibiotics to control enteric infections in calves and swine; products to treat canine separation anxiety; products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections; and other pharmaceutical products to treat staphylococcal and bacterial infections. The company distributes its products through independent wholesale distributors; and directly to pharmacies. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Conterno Enrique A | Sr. VP & Pres., Lilly Diabetes | May 15 | Sale | 56.15 | 5,000 | 280,750 | 72,177 | May 16 04:06 PM | | Simmons Jeffrey N | SVP&Pres.,Elanco Animal Health | May 10 | Sale | 54.49 | 10,000 | 544,900 | 51,750 | May 13 03:37 PM | | Conterno Enrique A | Sr. VP & Pres., Lilly Diabetes | May 01 | Option Exercise | 0.00 | 10,000 | 0 | 81,875 | May 01 03:46 PM | | Simmons Jeffrey N | SVP&Pres.,Elanco Animal Health | May 01 | Option Exercise | 0.00 | 10,000 | 0 | 66,385 | May 01 03:44 PM | | Conterno Enrique A | Sr. VP & Pres., Lilly Diabetes | Apr 15 | Sale | 57.10 | 5,000 | 285,500 | 71,875 | Apr 16 11:46 AM | | Mahony Susan | SVP & Pres., Lilly Oncology | Mar 26 | Sale | 56.00 | 5,000 | 280,000 | 47,380 | Mar 26 01:03 PM | | Lundberg Jan M | EVP,Science&Tech and Pres. LRL | Mar 12 | Sale | 55.38 | 19,000 | 1,052,220 | 100,253 | Mar 13 11:21 AM | | Ricks David A | SVP and Pres, Lilly Bio-Meds | Feb 08 | Sale | 53.91 | 3,000 | 161,730 | 26,941 | Feb 11 03:59 PM | | Rice Derica W | EVP-Global Services and CFO | Feb 05 | Sale | 54.21 | 29,646 | 1,607,110 | 52,605 | Feb 07 09:29 AM | | Mahony Susan | SVP & Pres., Lilly Oncology | Feb 01 | Option Exercise | 0.00 | 22,943 | 0 | 57,380 | Feb 04 04:27 PM | | Lundberg Jan M | EVP,Science&Tech and Pres. LRL | Feb 01 | Option Exercise | 0.00 | 77,456 | 0 | 134,910 | Feb 04 04:26 PM | | LECHLEITER JOHN C | Chairman, President, and CEO | Feb 01 | Option Exercise | 0.00 | 132,367 | 0 | 529,223 | Feb 04 04:25 PM | | Conterno Enrique A | Sr. VP & Pres., Lilly Diabetes | Feb 01 | Option Exercise | 0.00 | 31,768 | 0 | 91,797 | Feb 04 04:23 PM | | Tapiero Jacques | SVP&Pres., Emerging Markets | Feb 01 | Option Exercise | 0.00 | 17,649 | 0 | 48,983 | Feb 04 04:33 PM | | Simmons Jeffrey N | SVP&Pres.,Elanco Animal Health | Feb 01 | Option Exercise | 0.00 | 17,649 | 0 | 64,566 | Feb 04 04:31 PM | | Rice Derica W | EVP-Global Services and CFO | Feb 01 | Option Exercise | 0.00 | 52,947 | 0 | 106,792 | Feb 04 04:30 PM | | Peterson Barton R | Sr. VP, Corp. Affairs & Comm. | Feb 01 | Option Exercise | 0.00 | 14,119 | 0 | 44,688 | Feb 04 04:28 PM | | Mahony Susan | SVP & Pres., Lilly Oncology | Feb 01 | Sale | 54.28 | 5,000 | 271,400 | 52,380 | Feb 04 04:27 PM | | Tapiero Jacques | SVP&Pres., Emerging Markets | Jan 30 | Sale | 54.14 | 15,000 | 812,100 | 31,334 | Jan 30 03:42 PM | | Ricks David A | SVP and Pres, Lilly Bio-Meds | Dec 03 | Option Exercise | 0.00 | 2,748 | 0 | 19,632 | Dec 05 01:35 PM | | Fry Stephen F | SVP, HR & Diversity | Dec 03 | Option Exercise | 0.00 | 3,778 | 0 | 22,811 | Dec 05 01:30 PM | | Zakrowski Donald A | Chief Accounting Officer | Dec 03 | Option Exercise | 0.00 | 1,641 | 0 | 1,641 | Dec 05 01:26 PM | | Mahony Susan | SVP & Pres., Lilly Oncology | Oct 24 | Sale | 50.45 | 10,000 | 504,500 | 20,620 | Nov 07 03:24 PM | | Tapiero Jacques | SVP&Pres., Emerging Markets | Oct 01 | Option Exercise | 0.00 | 12,500 | 0 | 31,244 | Oct 02 03:10 PM | | Conterno Enrique A | Sr. VP & Pres., Lilly Diabetes | Aug 01 | Sale | 44.16 | 5,000 | 220,800 | 27,012 | Aug 01 03:13 PM | | Conterno Enrique A | Sr. VP & Pres., Lilly Diabetes | Jul 02 | Sale | 43.00 | 5,000 | 215,000 | 32,012 | Jul 03 03:34 PM | | Tapiero Jacques | SVP&Pres., Emerging Markets | Jun 14 | Sale | 41.60 | 2,125 | 88,400 | 18,744 | Jun 18 09:31 AM | | Conterno Enrique A | Sr. VP & Pres., Lilly Diabetes | Jun 01 | Sale | 40.60 | 5,000 | 203,000 | 37,012 | Jun 04 03:52 PM |
|
|
|
|
|
|
